Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | F9 | P00740 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1919439 | 0.87 | ALDH1A1 (0.36) | ALDH1A1HPGDSMN1; SMN2F9 | |
| SCHEMBL1917746 | 0.83 | MEN1 (0.40) | ALDH1A1KDM4EGAAMAPTPOLB | |
| SCHEMBL1918064 | 0.82 | F9 (0.36) | KDM4EMAPTRECQLSMN1; SMN2KMT2A | |
| SCHEMBL1918976 | 0.81 | MAPT (0.40) | ALDH1A1KDM4EGAAMAPTSMN1; SMN2 | |
| SCHEMBL158113 | 0.77 | APEX1 (0.41) | ALDH1A1KDM4EPOLBRECQLMEN1 | |
| SCHEMBL3707021 | 0.77 | CA12 (0.42) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4437776 | 0.75 | ALDH1A1 (0.41) | ALDH1A1KDM4EPOLBRECQLMEN1 | |
| SCHEMBL5027701 | 0.69 | ADORA1 (0.35) | KDM4EMAPTPOLBKMT2A | |
| SCHEMBL1919435 | 0.69 | ACACB (0.40) | ALDH1A1F9 | |
| SCHEMBL13907870 | 0.68 | KMT2A (0.40) | ALDH1A1KDM4EMAPTPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3081213-B1 | TRICYCLIC COMPOUND | KYOWA KIRIN CO LTD (JP) | 2020-04-01 | — | — | EP | disclosed |
| US-9475805-B2 | Tricyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2016-10-25 | — | — | US | disclosed |
| EP-3081213-A1 | TRICYCLIC COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2016-10-19 | — | — | EP | disclosed |
| US-20150291587-A1 | TRICYCLIC COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2015-10-15 | — | — | US | disclosed |
| US-20130267711-A1 | TRICYCLIC COMPOUND | KYOWA HAKKO KIRIN CO LTD (JP) | 2013-10-10 | — | — | US | disclosed |
| US-8486980-B2 | Tricyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-07-16 | — | — | US | disclosed |
| US-20110201640-A1 | TRICYCLIC COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-08-18 | — | — | US | disclosed |
| EP-2327690-A1 | TRICYCLIC COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291587-A1 | TRICYCLIC COMPOUND | PPARA, PPARG, PPARD | ALDH1A1 1801/4885KDM4E 2084/4885GAA 2399/4885 |
| US-20130267711-A1 | TRICYCLIC COMPOUND | PPARA, PPARG, PPARD | ALDH1A1 1801/4885KDM4E 2084/4885GAA 2399/4885 |
| US-20110201640-A1 | TRICYCLIC COMPOUND | PPARG, PPARA, PPARD | ALDH1A1 2211/4885KDM4E 1708/4885GAA 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.